-
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)
Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
TLX as a Novel Therapeutic Target(Post)Danka Kozareva PhD Candidate, University College Cork The generation of neurons from stem cells The process of generating
Diabetic Retinopathy: premature cellular senescence and microvascular dysfunction(Post)By Pietro Maria Bertelli, PhD Candidate, Queens University Belfast Introduction Eye complications are very frequent in patients with diabetes, and thi
The Transformative Era of Induced Pluripotent Stem Cells in Modern Medicine(Post)The inception of induced pluripotent stem cells (iPSCs) has heralded a new dawn in the realm of biomedical research and regenerative medicine, setting the stage for groundbreaking advancements in
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Tezepelumab: A Breakthrough in Severe Asthma Treatment and Research(Post)Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in seve
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
Mycoplasma Detection Kit Troubleshooting: The Importance of Cell Confluence(Post)Quick answer A researcher's samples read negative at the standard 1-hour incubation on the MycoGenie Rapid Mycoplasma Detection Kit (MORV0011), but many turned positive after 2 hours.
The Battle of Antibiotics: Penicillin vs. Streptomycin(Post)Microbiology · AntibioticsPenicillin vs Streptomycin: The Battle of AntibioticsPenicillin and streptomycin are two of the most important antibiotics ever discovered — and they work in completely diffe
Xeroderma pigmentosum: Causes, Inheritance, Treatment and Diagnosis(Post)What is Xeroderma Pigmentosum? Xeroderma pigmentosum (XP) also known De Sanctis-Cacchione syndrome is a rare genetic disorder that affects the skin, eyes and central nervous system. It is ca
Cystic Fibrosis: Causes, Inheritance, Treatment and Diagnosis(Post)What is Cystic Fibrosis? Cystic fibrosis (CF) is a genetic disorder that impairs the body's ability to produce sweat and thick mucus. CF causes mucus to build up in t
Biomarkers in sepsis: Their Role in Early Detection and Management (Post)Sepsis, a life-threatening condition, is characterized by a dysregulated immune
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Troubleshooting high ELISA concentrations(Post)QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most
Biosimilar Antibodies(Page) Insulin Signaling and RTK: An Overview(Post)Cell Signalling · MetabolismInsulin Signalling & Receptor Tyrosine KinasesInsulin controls metabolism and growth through the insulin receptor — a receptor tyrosine kinase that branches into the
TCA Cycle Assays(Page) Farletuzumab: Advancing Antibody-Drug Conjugate Research in Ovarian Cancer(Post)Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Estrogen and Breast Cancer: a Nuclear (Receptor) War(Post)By Dr. Lisa Dwane, Postdoctoral Researcher, Royal College of Surgeons in Ireland The first link between estrogen and breast cancer was made in the late 1